Financial Results for the Third Quarter of Fiscal Year Ending March 31, 2014



February 04, 2014 Exchange where listed: TSE

Name of listed company : TERUMO CORPORATION (URL http://www.terumo.com/)

Company code number : 454

Representative: : Yutaro Shintaku, President and Representative Director
Please address all communications to : Masayuki Maruta, General Manager, Corporate Communication Dept.

Phone : +81 / 3-6742-8550

1. Consolidated financial highlights for the interim period ended December 2013 (From April 1, 2013 to December 31, 2013)

(Note: The amounts shown below ignore values of less than a million yen)

	Net sales		Operating income		Ordinary income		Net income	
	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%	(Millions of yen)	%
Nine months ended December, 2013	345,260	16.7	48,251	13.2	49,919	23.4	36,896	49.3
Nine months ended December, 2012	295,749	2.4	42,628	(14.5)	40,453	(12.7)	24,707	12.5

(Notes) 1. Comprehensive income: December 2013: 83,517million yen (104.4%) December 2012: 40,856million yen (- %)

2. Percentage represent increase (decrease) from the corresponding period in the prior fiscal year.

	Net income per share	Net income per share, fully diluted
	(Yen)	(Yen)
Nine months ended December, 2013	194.32	194.31
Nine months ended December, 2012	130.12	-

(2) Consolidated financial position

(Note: The amounts shown below ignore values of less than a million yen)

	Total assets	Net assets	Equity ratio	Net assets per share
	(Millions of yen)	(Millions of yen)	%	(Yen)
As at December 31, 2013	863,324	511,406	59.2	2,693.32
As at March 31, 2013	771,032	437,909	56.7	2,304.42

 $(Note)\ Shareholders'\ equity: December\ 31,\ 2013:\ 511,394\ million\ yen,\ March\ 31,\ 2013:\ 437,557\ million\ yen.$

2. Dividends

	Cash dividends per share					
	1st quarter	2nd quarter	3rd quarter	4th quarter	total	
	(Yen)	(Yen)	(Yen)	(Yen)	(Yen)	
Year ended March 31, 2013	-	22.00	-	22.00	44.00	
Year ending March 31, 2014	-	29.00	-			
Year ending March 31, 2014 (forecast)				29.00	58.00	

(Note) Revise of dividends forecast: None

3. Consolidated forecast for the year ending March 2014 (From April 1, 2013 to March 31, 2014)

	Net sales		Operating income		Ordinary income		Net income		Net income per share
	(Millions of yen)	%	(Yen)						
Year ending March, 2014	460,000	14.3	70,000	31.5	67,500	31.4	42,000	(10.7)	221.20

Forecast for fiscal year ending March, 2014 which was announced on May 9, 2013 has not been revised. (Assumed exchange rate for the fiscal year ending March, 2014: USD1=JPY100, EUR1=JPY134)

^{2.} Among the information that Terumo discloses, forecasts of financial performance on future projections contain potential risks and uncertainty since these are forecasts on projections made by Terumo based on limited information available at the moment of disclosure. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition.

4. Consolidated Financial Statements

(1) Consolidated Balance Sheets

(Millions of yen)

	As at March	31, 2013	As at December 31, 2013		
	Amount	%	Amount	%	
(Assets)					
I Current assets	286,955	37.2%	319,205	37.0%	
Cash and deposits	78,201		94,866		
Notes and accounts receivable - trade	95,008		108,575		
Inverntories	85,179		96,248		
Deferred tax assets	11,258		10,384		
Other	18,528		10,522		
Allowance for doubtful accounts	(1,220)		(1,391)		
II Noncurrent assets	483,770	62.8%	543,116	62.9%	
1. Property, plant and equipment	144,824	18.8%	167,978	19.5%	
Buildings and structures	48,966		53,066		
Machinery, equipment and vehicles	46,366		51,538		
Land	21,827		21,785		
Lease assets	704		521		
Construction in progress	17,794		31,070		
Other	9,165		9,996		
2. Intangible assets	296,634	38.5%	322,360	37.3%	
Goodwill	149,322		160,343		
Customer relationships	90,706		97,404		
Other	56,604		64,612		
3. Investments and other assets	42,311	5.5%	52,778	6.1%	
Investment securities	30,304		37,130		
Deferred tax assets	5,153		3,266		
Other	6,852		12,380		
III Deferred assets	306	0.0%	1,001	0.1%	
Total assets	771,032	100.0%	863,324	100.0%	

(Millions of yen)

	(Millions					
	As at March 31, 2013 As at De			ber 31,		
	Amount	%	Amount	%		
(Liabilities)						
I Current liabilities	115,844	15.0%	126,071	14.6%		
Notes and accounts payable - trade	37,515		36,922			
Short - term loans payable	18,046		10,500			
Current portion of long - term loans payable	3,762		4,460			
Lease obligations	277		205			
Income taxes payable	2,609		14,637			
Deferred tax liabilities	35		83			
Provision for bonuses	4,834		2,508			
Provision for directors' bonuses	109		81			
Notes and accounts payable - facilities	6,624		12,533			
Asset retirement obligations	420		-			
Other	41,611		44,137			
II Noncurrent liabilities	217,278	28.2%	225,846	26.2%		
Bonds payable	80,000		80,000			
Long - term loans payable	78,712		82,160			
Lease obligations	439		308			
Deferred tax liabilities	49,659		54,072			
Provision for retirement benefits	1,247		1,567			
Provision for directors' retirement benefits	198		66			
Asset retirement obligations	155		157			
Other	6,865		7,514			
Total liabilities	333,122	43.2%	351,917	40.8%		
(Net assets)						
I Shareholders' equity	419,999	54.5%	447,200	51.8%		
Capital stock	38,716		38,716			
Capital surplus	52,103		52,103			
Retained earnings	329,188		356,400			
Treasury stock	(9)		(20)			
II Accumulated other comprehensive income	17,557	2.3%	64,194	7.4%		
Valuation difference on available - for - sale securities	7,458		11,909			
Deferred gains or losses on hedges	-		(16)			
Foreign currency translation adjustment	10,099		52,302			
III Subscription rights to shares	-	-	11	0.0%		
IV Minority interests	352	0.0%	-	-		
Total net assets	437,909	56.8%	511,406	59.2%		
Total liabilities and net assets	771,032	100.0%	863,324	100.0%		

(2) (Consolidated Statements of Income	T		i		(Mill	ions of yen)	
			ne months mber 31, 2		For nine months ended December 31, 2013			
		Am	ount	%	Am	ount	%	
_	NI-AI		005 740	100.00/		0.45 0.00	100.00/	
I	Net sales		295,749	100.0%		345,260	100.0%	
II	Cost of sales		142,261	48.1%		166,599	48.3%	
TTT	Gross profit Selling, general and administrative expenses		153,487 110,859	51.9% 37.5%		178,661 130,409	51.7% 37.7%	
111	Operating income		42,628	14.4%		48,251	14.0%	
TV	Non-operating income		42,026	14.470		40,231	14.0%	
10	-	001			907			
	Interest income	221			287			
	Dividends income	191			226			
	Royalty income	87			81			
	Foreign exchange gains	15			4,664			
	Equity in earnings of affiliates	134			96			
	Other	575	1,225	0.4%	776	6,131	1.8%	
V	Non-operating expenses							
	Interest expenses	948			1,124			
	Sales discounts	447			479			
	Loss on disposal of inventories	560			75			
	Other	1,443	3,399	1.1%	2,784	4,464	1.3%	
	Ordinary income		40,453	13.7%		49,919	14.5%	
VI	Extraordinary income							
	Gain on sales of noncurrent assets	47			7			
	Gain on transfer of business	-			299			
	Subsidy income	875			-			
	Settlement received	-	922	0.3%	6,000	6,307	1.8%	
VII	Extraordinary expenses							
	Loss on disposal of noncurrent assets	451			216			
	Impairment loss	-			561			
	Directors' retirement benefits	-			33			
	Loss on liquidation of business	-			881			
	Loss on valuation of golf club memberships	3			-			
	Environmental expenses	390	845	0.3%	-	1,693	0.5%	
	Income before income taxes		40,530	13.7%		54,533	15.8%	
	Income taxes-current	17,564			18,041			
	Income taxes-deferred	(1,773)	15,790	5.3%	(434)	17,606	5.1%	
	Income before minority interests		24,739	8.4%		36,926	10.7%	
	Minority interests in income		32	0.0%		30	0.0%	
	Net income		24,707	8.4%		36,896	10.7%	

	For nine mo December		For nine mo	
	Amo	unt	Amo	ount
I Income before minority interests II Other comprehensive income securities		24,739		36,926
Valuation difference on available-for-sale securities Deferred gains or losses on hedges Foreign currency translation adjustments	1,678 (38) 14,476		4,450 (16) 42,158	
Share of other comprehensive income of associates accounted for using equity method	1	16,116	(2)	46,590
Comprehensive income		40,856		83,517
Attributable to: Shareholders of Terumo Corporation Minority interests		40,826 29		83,530 (13)

5. Segment Information

[Reportable Segments]

(1) The Third Quarter of Fiscal Year Ended March 31, 2013

(Millions of yen)

	For nine months ended						
		December 31, 2012					
	General	Cardiac &	Blood				
	Hospital	Vascular	Management				
	Business	Business	Business	Subtotal	Adjustment	Total	
Sales and operating income:							
Sales to customer	119,791	122,305	53,652	295,749	-	295,749	
Internal sales	-	-	-	-	-	-	
Sales total	119,791	122,305	53,652	295,749	-	295,749	
Segment income (loss)	18,651	19,530	1,880	40,061	2,566	42,628	

Notes:

- $^{1\cdot}$ The 2,566 million yen adjustment to segment profit is the sum of the 570 million yen for inventories and the 1,995 million yen for others.
- 2. Segment profit is adjusted to be consistent with operating income shown on the quarterly consolidated income statement.

(2) The Third Quarter of Fiscal Year Ending March 31, 2014

(Millions of yen)

• •		- 0					
		For nine months ended					
		December 31, 2013					
	General	Cardiac &	Blood				
	Hospital	Vascular	Management				
	Business	Business	Business	Subtotal	Adjustment	Total	
Sales and operating income:							
Sales to customer	123,910	153,873	67,476	345,260	-	345,260	
Internal sales	-	-	-	-	-	-	
Sales total	123,910	153,873	67,476	345,260	-	345,260	
Segment income (loss)	16,218	30,081	3,042	49,342	(1,090)	48,251	

Notes:

- 1. The (1,090) million yen adjustment to segment profit is the sum of the (626) million yen for inventories and the (464) million yen for others.
- 2 . Segment profit is adjusted to be consistent with operating income shown on the quarterly consolidated income statement.

(Note) Main products belonging to each business segment

Business segments	Main products
General Hospital business	
Disposable medical devices and medical electronics	Syringes, Needles, Blood collection tubes, Solution sets, I.V.catheters, Infusion pumps, Syringe pumps, etc.
Pharmaceuticals	I.V.solutions, Nutritious food, Prefilled syringes, CAPD systems, etc.
Diabetes care products	Blood glucose monitoring systems
Consumer Healthcare business	Digital Thermometers, Blood pressure monitors, Blood glucose monitors (OTC), etc.
Cardiac and Vascular business	
Interventional systems	$\label{lem:condition} Angiographic catheters, PTCA \ balloon \ catheters, Coronary \ stents, \ Neuro \ interventional \ coils, etc.$
Cardiovascular systems	Oxygenerators, Cardio-pulmonary bypass system, Left ventricular assist system, etc.
Vascular grafts	Artificial vascular grafts, Stent grafts
Blood Management business	Blood bags, Automated blood collection system, Therapeutic apheresis system, Cell expansion system, etc.